Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2022 Mar 14

PMID 35285488

Authors

Helena J Janse van Rensburg

Pavlina Spiliopoulou

Lillian L Siu

Affiliations

Soon will be listed here.

Abstract

Circulating biomarkers have emerged as valuable surrogates for evaluating disease states in solid malignancies. Their relative ease of access and rapid turnover has bolstered clinical applications in monitoring treatment efficacy and cancer progression. In this review, the roles of various circulating biomarkers in monitoring treatment response are described. Non-specific markers of disease burden, tumor markers (eg CA 125, CEA, PSA, etc.), circulating tumor cells, nucleic acids, exosomes, and metabolomic arrays are highlighted. Specifically, the discovery of each of these markers is reviewed, with examples illustrating their use in influencing treatment decisions, and barriers to their application noted where these exist. Finally, opportunities for future work using these circulating biomarkers are discussed.

Citing Articles

Stimulus-responsive smart bioactive glass composites for repair of complex tissue defects.

Yang Y, Qiu Y, Lin C, Chen X, Zhao F Theranostics. 2025; 15(5):1760-1786.

PMID: 39897548 PMC: 11780539. DOI: 10.7150/thno.104944.

Targeted treatments after chemoradiotherapy failure in a patient with relapsed, advanced non‑small cell lung cancer with on‑therapy circulating tumor biomarker monitoring: A case report.

Bi Y, Xia C, Zhang X, Liu H Oncol Lett. 2023; 26(3):407.

PMID: 37600327 PMC: 10436159. DOI: 10.3892/ol.2023.13993.

Potential Role of Tumor-Derived Exosomes in Non-Small-Cell Lung Cancer in the Era of Immunotherapy.

Tartarone A, Lerose R, Tartarone M, Aieta M Life (Basel). 2022; 12(12).

PMID: 36556468 PMC: 9781579. DOI: 10.3390/life12122104.

The Role of Cell-Free DNA in Cancer Treatment Decision Making.

Telekes A, Horvath A Cancers (Basel). 2022; 14(24).

PMID: 36551600 PMC: 9776613. DOI: 10.3390/cancers14246115.

Functional and quantitative evaluation of the 20S proteasome in serum and intracellular in145 moroccan patients with hematologic malignancies.

Filali H, El Yaagoubi O, Ayoub Lahmadi , Quessar A, Antri S, Samaki H Clin Proteomics. 2022; 19(1):41.

PMID: 36380291 PMC: 9664591. DOI: 10.1186/s12014-022-09375-9.

References

Egberts F, Kotthoff E, Gerdes S, Egberts J, Weichenthal M, Hauschild A . Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Eur J Cancer. 2011; 48(5):695-702. DOI: 10.1016/j.ejca.2011.08.007. View

Daher S, Lawrence Y, Dudnik E, Hanovich E, Urban D, Peled N . Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers. Front Oncol. 2021; 11:625668. PMC: 8335163. DOI: 10.3389/fonc.2021.625668. View

Jia Z, Zhang J, Wang Z, Wang B, Wang L, Cao J . An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer. Oncotarget. 2018; 9(12):10714-10722. PMC: 5828224. DOI: 10.18632/oncotarget.24246. View

Campitelli M, Jeannot E, Peter M, Lappartient E, Saada S, De la Rochefordiere A . Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients. PLoS One. 2012; 7(8):e43393. PMC: 3427328. DOI: 10.1371/journal.pone.0043393. View

El-Sharkawi D, Basu S, Ocampo C, Qian W, DSa S, Hoskin P . Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin,.... Leuk Lymphoma. 2012; 53(10):1949-52. DOI: 10.3109/10428194.2012.679360. View

Iwanicki-Caron I, Di Fiore F, Roque I, Astruc E, Stetiu M, Duclos A . Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol. 2008; 26(22):3681-6. DOI: 10.1200/JCO.2007.15.0904. View

Wishart D . Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016; 15(7):473-84. DOI: 10.1038/nrd.2016.32. View

Tilly H, Dreyling M . Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v172-4. DOI: 10.1093/annonc/mdq203. View

Berteloot A, Chabot J, Hugon J . Turnover of mouse intestinal brush border membrane proteins and enzymes in organ culture. A direct evaluation from studies on the evolution of enzyme activities during the culture. Biochim Biophys Acta. 1981; 678(3):423-36. DOI: 10.1016/0304-4165(81)90124-0. View

10.

Rustin G . Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann Oncol. 2011; 22 Suppl 8:viii45-viii48. DOI: 10.1093/annonc/mdr471. View

11.

Thery C, Zitvogel L, Amigorena S . Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569-79. DOI: 10.1038/nri855. View

12.

Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S . Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017; 84:212-218. DOI: 10.1016/j.ejca.2017.07.027. View

13.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

14.

Rothwell D, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E . Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019; 25(5):738-743. DOI: 10.1038/s41591-019-0380-z. View

15.

Forkasiewicz A, Dorociak M, Stach K, Szelachowski P, Tabola R, Augoff K . The usefulness of lactate dehydrogenase measurements in current oncological practice. Cell Mol Biol Lett. 2020; 25:35. PMC: 7285607. DOI: 10.1186/s11658-020-00228-7. View

16.

Tang Y, Zhang P, Wang Y, Wang J, Su M, Wang Y . The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer. Front Immunol. 2020; 11:604. PMC: 7158891. DOI: 10.3389/fimmu.2020.00604. View

17.

Andre F, Schartz N, Movassagh M, Flament C, Pautier P, Morice P . Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002; 360(9329):295-305. DOI: 10.1016/S0140-6736(02)09552-1. View

18.

Halabi S, Lin C, Kelly W, Fizazi K, Moul J, Kaplan E . Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014; 32(7):671-7. PMC: 3927736. DOI: 10.1200/JCO.2013.52.3696. View

19.

Dawson S, Tsui D, Murtaza M, Biggs H, Rueda O, Chin S . Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13):1199-209. DOI: 10.1056/NEJMoa1213261. View

20.

Fahmueller Y, Nagel D, Hoffmann R, Tatsch K, Jakobs T, Stieber P . Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer. 2012; 132(10):2349-58. DOI: 10.1002/ijc.27894. View